Amgen Inc. on Tuesday reported positive topline data from a Phase 2 study evaluating olpasiran in the reduction of lipoprotein(a), reported to be an independent risk factor for cardiovascular disease.
The Thousand Oaks, Calif., biotechnology company said the study showed significant, sustained reduction in lipoprotein(a) in adults with levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease.
Olpasiran is designed to lower the body's production of apolipoprotein(a), a key component of lipoprotein(a) that has been associated with an increased risk of cardiovascular events.
Amgen said olpasiran showed a reduction from baseline in lipoprotein(a) of up to or greater than 90% at week 36, the primary endpoint, and week 48, the end of the treatment period, for the majority of doses, adding that no new safety concerns were identified.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.